Miramar Labs Announces New Optimized Treatment Protocol to Increase miraDry® Patient Volume and Satisfaction

Print 30 July 2015

SANTA CLARA, California, July 30, 2015 /PRNewswire/ -- Miramar® Labs, a global aesthetics company, today announced the release of the Optimized Treatment Protocol (OTP) in Europe and the Middle East.  The new protocol, designed to increase patient satisfaction and reduce treatment times, should further expand the potential patient population for the miraDry® System which eliminates underarm sweat and odor glands.

The miraDry System received CE Mark approval in December 2013 following US FDA clearance in January 2011. The Optimized Treatment Protocol is the ideal approach for improving the miraDry value proposition for both physicians and patients. OTP continues to build upon a procedure with one of the highest efficacy and patient satisfaction records among aesthetic treatments.

"The new OTP has made a significant difference in my miraDry business," said Dr. Grant Stevens of Marina Plastic Surgery in Marina Del Rey, Calif. "In the short time since I started using the new protocol my patient volume has more than doubled and continues to grow.  The treatment is ideally suited for my cosmetic patients and the new protocol has enhanced the treatment in such a way that I feel compelled to tell every patient about it.  With permanent benefits and minimal downtime, there is no better solution for treating unwanted underarm sweat." Dr. Stevens is also clinical professor of surgery at the University of Southern California.

Miramar Lab's proprietary miraWave® technology –use of precisely controlled microwave energy - is the foundation of the miraDry System.  It is a significant technological advancement in the aesthetic market. The miraDry system is currently distributed in over forty [40] countries worldwide.  The company reports over 40,000 miraDry treatments, and sweat reduction is one of the fastest growing segments in aesthetics.

For more details on the Optimized Treatment Protocol click here for a live recording of the recent OTP Webinar.

About Miramar Labs:     
Founded in 2006, Miramar Labs is a privately owned global medical device company dedicated to bringing the next generation energy modality to the field of dermatology.  Supported by rigorous clinical research, Miramar Labs is focused on addressing aesthetic medical conditions for which there are significant unmet clinical needs. The company's first priority is advancing aesthetic treatments using its proprietary miraWave technology. Physicians and patients are encouraged to visit www.miramarlabs.com for additional information about Miramar Labs.

Return